Amount of astigmatism and pupil size affect UCVA

Article

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Dr Kazutaka Kamiya et al., Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan, studied 20 healthy eyes of 20 volunteers. With-the-rule and against-the-rule astigmatism were created after cycloplegic refraction was fully treated. UCVA was measured using artificial pupils of 1 to 5 mm in each eye. To perform a statistical analysis the clinicians used the mean value of three measurements.

Eyes with with-the-rule astigmatism of 1, 2 and 3 D, logMAR UCVA was 0.04±0.08, 0.09±0.09 and 0.16±0.16 for pupils of 1 mm, −0.01±0.09, 0.12±0.15 and 0.33±0.24 for 2 mm pupils, 0.02±0.09, 0.20±0.19 and 0.46±0.30 for 3 mm pupils, 0.02±0.08, 0.24±0.20 and 0.48±0.21 for 4 mm pupils, and 0.08±0.10, 0.33±0.18 and 0.53±0.22 for 5 mm pupils, respectively. Eyes with against-the-rule astigmatism achieved similar results.

The findings advise that, as well as the amount of astigmatism, pupil size should also be considered when improving visual performance in astigmatic eyes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.